Verastem Inc. presented data from its phase 1 trial of duvelisib as part of a combination treatment for relapsed or refractory T-cell lymphomas.
The study evaluated patients who received oral duvelisib with either Celgene Corp.'s Istodax, also known as romidepsin, or Takeda Pharmaceutical Co. Ltd.'s Velcade, also known as bortezomib. Patients were dosed on 28-day cycles.
Overall response rates of 60% and 35% were reported in the Istodax and Velcade groups, respectively.
Duvelisib had an acceptable safety profile in the trial.
Relapsed or refractory T-cell lymphomas are a rare and aggressive type of non-Hodgkin lymphoma, a cancer that starts in white blood cells.
Verastem said Duvelisib is also being developed to treat relapsed or refractory chronic lymphocytic leukemia, small lymphocytic lymphoma and follicular lymphoma.
